Over 10 years experience of Traceability Solutions
By Pharmatrax Author
Category: Technoloy
No CommentsThe post-World War II era was a golden age for the pharmaceutical industry. Large pharmaceutical companies such as Merck and Eli Lilly churned out new antibiotics, vaccines and medications at an astonishing rate that radically changed people’s lives for the better. Today, however, innovation in the pharmaceutical industry is very different. Tighter regulations, expiring patents and the growth in genomics have all affected the industry.
The sheer size of the industry makes it important for anyone involved in healthcare to stay abreast of pharmaceutical industry trends. Multinational healthcare firm Iqvia projects that the global pharmaceutical market will grow to $1.6 trillion by 2025. Individuals who are interested in pursuing a Healthcare MBA degree can benefit from gaining an understanding of trends that will shape the future of the industry.
With the flattening of growth in pharma sales in developed countries, drug makers are increasingly looking to emerging markets for new sources of growth and revenue. This means pharmaceutical companies will focus on global competencies with strategies tailored for local markets to stay competitive.
Market research firm Imarc projects that the global “pharmerging” market — which includes countries that presently have a low position in the market but are rapidly growing — will experience a compound annual growth rate of 10.4% from 2021 to 2026. Imarc cites the following reasons for growth in the pharmerging market:
The trend toward cost containment in healthcare is driving the heated debate about access to costly drug treatments. Healthcare executives are increasingly involved in formulary decisions. Pharmaceutical companies will need to provide more evidence-based data on health outcomes to justify a particular therapy or medication. Value needs to be communicated to all stakeholders: insurers, healthcare providers and patients. Collaboration between bioinformaticists and marketing is necessary to develop marketing materials designed for each audience, focusing on evidence and positive health outcomes.
As one of the most prominent pharmaceutical industry trends, mergers and acquisitions have shaped the pharmaceutical industry more significantly than other industries. This is because the pharma industry is high risk; few products make it to market, and fewer still recoup the cost of R&D. The focus of mergers and acquisitions will change, too, from accumulating a large portfolio of products to concentrating on areas of strength and shedding areas of weakness. An example of this is GlaxoSmithKline’s (GSK) asset swap with Novartis, which strengthened GSK’s vaccine position and reinforced Novartis’s prominence in cancer drugs.
Consulting firm McKinsey & Company reported that, immediately prior to the COVID-19 pandemic, pharma merger and acquisition activity had reached an all-time high, with $414 billion in deals in 2019. Although merger and acquisition activity decreased during the pandemic, McKinsey & Company expects that the excess cash reserves that pharmaceutical companies have accumulated will enable those companies to resume merger and acquisition activity at a pace similar to that prior to the pandemic.
The FDA’s Current Good Manufacturing Practices (CGMP) guidelines will require additional investments in technology and IT to reduce costs, increase flexibility, adapt to new regulations and streamline the process from R&D to manufacturing. Process Analytical Technology (PAT), product lifecycle management tools and Quality by Design (QbD) technology help companies prepare for live licensing and reduce business risks and overall development and manufacturing costs. Given the rapidly evolving regulatory framework, these tech investments become even more important for agile responses.
The pharma industry is poised for significant change in the coming decades. For today’s savvy pharma executives, these are the trends to watch.
The increase in prescription drug costs is a pharmaceutical industry trend for which there is ample evidence. For example:
Employee benefits consulting firm JP Griffin Group cites specialty drugs as a significant driver of increases in drug prices. The number of specialty drugs and their use are both rising, and the prices for specialty drugs are increasing more rapidly than for nonspecialty drugs.
The Peter G. Peterson Foundation offers additional reasons for increases in drug prices, including the following:
The growing use of artificial intelligence is an important trend in the pharmaceutical industry. According to PharmaExec.com, the industry can use artificial intelligence to do things such as:
Research firm MarketsandMarkets projects that the size of the global artificial intelligence healthcare market will grow from $4.9 billion in 2020 to $45.2 billion by 2026, and the primary drivers of that growth will be:
The pharmaceutical industry is also wading into blockchain technology, which creates a transaction ledger to prevent hacking and alterations of data. According to TechHQ, blockchain technology could help the pharmaceutical industry:
Pharmaceutical industry trends will play a big part in the careers of individuals who aspire to become leaders in healthcare. If leading the charge in the challenging world of healthcare interests you, explore George Washington University’s online Healthcare Master of Business Administration program to learn how the program can help you pursue your professional goals. Take the first step toward a rewarding career today.
Source:https://healthcaremba.gwu.edu/blog/pharmaceutical-industry-trends/